Synthesis and evaluation of novel 4-[(3H,3aH,6aH)-3-phenyl)-4,6-dioxo-2- phenyldihydro-2H-pyrrolo[3,4-d]isoxazol-5(3H,6H,6aH)-yl]benzoic acid derivatives as potent acetylcholinesterase inhibitors and anti-amnestic agents

Bioorganic and Medicinal Chemistry

Volumn 20, Issue 1, 2012, Pages 521-530

  Anand, Preet ^a   Singh, Baldev ^a  

^a PUNJABI UNIVERSITY   (India)

Author keywords

Acetyl cholinesterase; Azomethine N oxides; Morris water maze; Pyrrolo isoxazole benzoic acid

Indexed keywords

4 [(3 PHENYL) 4,6 DIOXO 2 PHENYLDIHYDRO 2H PYRROLO[3,4 D]ISOXAZOL 5 YL]BENZOIC ACID; 4 [(3 PHENYL) 4,6 DIOXO 2 PHENYLDIHYDRO 2H PYRROLO[3,4 D]ISOXAZOL 5 YL]BENZOIC ACID DERIVATIVE; 4 [3 (2 CHLOROPHENYL) 4,6 DIOXO 2 PHENYLDIHYDRO 2H PYRROLO[3,4 D]ISOXAZOL 5 YL]BENZOIC ACID; 4 [3 (2 CHLOROPHENYL) 4,6 DIOXO 2P TOLYDIHYDRO 2H PYRROLO[3,4 D]ISOXAZOL 5 YL]BENZOIC ACID; 4 [3 (2 HYDROXYPHENYL) 4,6 DIOXO 2 PHENYLDIHYDRO 2H PYRROLO[3,4 D]ISOXAZOL 5 YL]BENZOIC ACID; 4 [3 (2 HYDROXYPHENYL) 4,6 DIOXO 2P TOLYDIHYDRO 2H PYRROLO[3,4 D]ISOXAZOL 5 YL]BENZOIC ACID; 4 [3 (2 METHOXYPHENYL) 4,6 DIOXO 2 PHENYLDIHYDRO 2H PYRROLO[3,4 D]ISOXAZOL 5 YL]BENZOIC ACID; 4 [3 (2 METHOXYPHENYL) 4,6 DIOXO 2P TOLYDIHYDRO 2H PYRROLO[3,4 D]ISOXAZOL 5 YL]BENZOIC ACID; 4 [3 (2 NITROPHENYL) 4,6 DIOXO 2 PHENYLDIHYDRO 2H PYRROLO[3,4 D]ISOXAZOL 5 YL]BENZOIC ACID; 4 [3 (2 NITROPHENYL) 4,6 DIOXO 2P TOLYDIHYDRO 2H PYRROLO[3,4 D]ISOXAZOL 5 YL]BENZOIC ACID; 4 [3 (3 CHLOROPHENYL) 4,6 DIOXO 2 PHENYLDIHYDRO 2H PYRROLO[3,4 D]ISOXAZOL 5 YL]BENZOIC ACID; 4 [3 (3 CHLOROPHENYL) 4,6 DIOXO 2P TOLYDIHYDRO 2H PYRROLO[3,4 D]ISOXAZOL 5 YL]BENZOIC ACID; 4 [3 (3 METHOXYPHENYL) 4,6 DIOXO 2 PHENYLDIHYDRO 2H PYRROLO[3,4 D]ISOXAZOL 5 YL]BENZOIC ACID; 4 [3 (3 METHOXYPHENYL) 4,6 DIOXO 2P TOLYDIHYDRO 2H PYRROLO[3,4 D]ISOXAZOL 5 YL]BENZOIC ACID; 4 [3 (4 CHLOROPHENYL) 4,6 DIOXO 2 PHENYLDIHYDRO 2H PYRROLO[3,4 D]ISOXAZOL 5 YL]BENZOIC ACID; 4 [3 (4 CHLOROPHENYL) 4,6 DIOXO 2P TOLYDIHYDRO 2H PYRROLO[3,4 D]ISOXAZOL 5 YL]BENZOIC ACID; 4 [3 (4 HYDROXYPHENYL) 4,6 DIOXO 2 PHENYLDIHYDRO 2H PYRROLO[3,4 D]ISOXAZOL 5 YL]BENZOIC ACID; 4 [3 (4 HYDROXYPHENYL) 4,6 DIOXO 2P TOLYDIHYDRO 2H PYRROLO[3,4 D]ISOXAZOL 5 YL]BENZOIC ACID; 4 [3 (4 METHOXYPHENYL) 4,6 DIOXO 2 PHENYLDIHYDRO 2H PYRROLO[3,4 D]ISOXAZOL 5 YL]BENZOIC ACID; 4 [3 (4 METHOXYPHENYL) 4,6 DIOXO 2P TOLYDIHYDRO 2H PYRROLO[3,4 D]ISOXAZOL 5 YL]BENZOIC ACID; 4 [3 (4 NITROPHENYL) 4,6 DIOXO 2 PHENYLDIHYDRO 2H PYRROLO[3,4 D]ISOXAZOL 5 YL]BENZOIC ACID; 4 [3 (4 NITROPHENYL) 4,6 DIOXO 2P TOLYDIHYDRO 2H PYRROLO[3,4 D]ISOXAZOL 5 YL]BENZOIC ACID; 4 [3 PHENYL 4,6 DIOXO 2P TOLYDIHYDRO 2H PYRROLO[3,4 D]ISOXAZOL 5 YL]BENZOIC ACID; CHOLINESTERASE; CHOLINESTERASE INHIBITOR; DONEPEZIL; SCOPOLAMINE; UNCLASSIFIED DRUG;

ALZHEIMER DISEASE; ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; CHEMICAL MODIFICATION; CONTROLLED STUDY; CYCLIZATION; DRUG MECHANISM; DRUG SCREENING; DRUG STRUCTURE; DRUG SYNTHESIS; ENZYME INHIBITION; IC 50; IN VITRO STUDY; IN VIVO STUDY; MAZE TEST; MEMORY CONSOLIDATION; MOLECULAR DOCKING; MOUSE; NONHUMAN; RAT; STEREOISOMERISM; STRUCTURE ACTIVITY RELATION; SUBSTITUTION REACTION; TISSUE HOMOGENATE;

ACETYLCHOLINESTERASE; ANIMALS; BENZOIC ACIDS; BINDING SITES; BUTYRYLCHOLINESTERASE; CATALYTIC DOMAIN; CHOLINESTERASE INHIBITORS; COMPUTER SIMULATION; CYCLIZATION; ENZYME ACTIVATION; FEMALE; HUMANS; ISOXAZOLES; MALE; MAZE LEARNING; MEMORY; MICE; NEUROPROTECTIVE AGENTS; PYRROLES; RATS; STEREOISOMERISM;

MUS; RATTUS;

EID: 84855207251     PISSN: 09680896     EISSN: 14643391     Source Type: Journal    
DOI: 10.1016/j.bmc.2011.05.027     Document Type: Article

References (21)

1. M. Colombres, J.P. Sagal, and N.C. Inestrosa Curr. Pharm. Des. 10 2004 3121
2. M. Bartolini, C. Bertucci, V. Cavrini, and V. Andrisano Biochem. Pharmacol. 65 2003 407
3. T. Rees, P.I. Hammond, H. Soreq, S. Younkin, and S. Brimijoin Neurobiol. Aging 24 2003 777
4. J. Trujillo-Ferrara, L. Montoya Cano, and M. Espinoza-Fonseca Bioorg. Med. Chem. Lett. 13 2003 1825
5. J. Trujillo-Ferrara, I. Vázquez, J. Espinosa, R. Santillan, N. Farfán, and H. Höpfl Eur. J. Pharm. Sci. 18 2003 313
6. J. Correa-Basurto, I.V. Alcántara, L.M. Espinoza-Fonseca, and J.G. Trujillo-Ferrara Eur. J. Med. Chem. 40 2005 732
7. E.J. Barreiro, C.A. Camara, H. Verli, L. Brazil-Más, N.G. Castro, W.M. Cintra, Y. Aracava, C.R. Rodrigues, and C.A. Fraga J. Med. Chem. 27 2003 1144
8. A. Villalobos, T.W. Butler, D.S. Chapin, Y.L. Chen, S.B. DeMattos, J.L. Ives, S.B. Jones, D.R. Liston, A.A. Nagel, and D.M. Nason J. Med. Chem. 38 1995 2802
9. S.Y. Lee, Y.S. Choe, Y.R. Kim, J.Y. Paik, B.W. Choi, S.E. Kim, K.H. Lee, Y. Choi, and B.T. Kim Nucl. Med. Commun. 25 2004 591
10. I. Lee, Y.S. Choe, E.K. Ryu, B.W. Choi, J.Y. Choi, Y. Choi, K.H. Lee, and B.T. Kim Nucl. Med. Commun. 28 2007 561
11. K. Isomae, S. Morimoto, H. Hasegawa, K. Morita, and J. Kamei Eur. J. Pharmacol. 465 2003 97
12. K.K. Singal, and B. Singh Indian J. Chem. 23B 1984 657
13. B. Singh, and K.K. Singal Indian J. Chem. 38B 1999 292
14. B. Singh, and K.K. Singal Indian J. Chem. 38B 1999 93
15. J. Wiesner, Z. Kriz, K. Kuca, D. Jun, and J. Koca J. Enzyme Inhib. Med. Chem. 22 2007 417
16. G. Johnson, and S.W. Moore Curr. Pharm. Des. 12 2006 217
17. J.M. Bui, and J.A. McCammon Chem. Biol. Interact. 157-158 2005 357
18. G.L. Ellmann, D. Courtney, V. Andres Jr., and R.M. Featherstone Biochem. Pharmacol. 7 1961 88
19. B. Sharma, N. Singh, M. Singh, and A.S. Jaggi Pharmacol. Biochem. Behav. 89 2008 535
20. P. Jia, R. Sheng, J. Zhang, L. Fang, Q. He, B. Yang, and Y. Hu Eur. J. Med. Chem. 44 2009 772
21. R.G.M. Morris J. Neurosci. Methods 11 1984 47 60